Fracture healing in HIV-positive populations

Journal of Bone and Joint Surgery - Series B

Volumn 90, Issue 8, 2008, Pages 988-994

  Richardson, J ^a   Hill, A M ^a   Johnston, C J C ^a   McGregor, A ^a   Norrish, A R ^a,b   Eastwood, D ^a,c   Lavy, C B D ^a,d  

^a CHARING CROSS HOSPITAL   (United Kingdom)

^b Tropical Surgery Research and Training Unit   (Zambia)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^d NUFFIELD ORTHOPAEDIC CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTIRETROVIRUS AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D;

BONE DENSITY; BONE METABOLISM; BONE NECROSIS; BONE REMODELING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG EFFECT; FRACTURE FIXATION; FRACTURE HEALING; FRAGILITY FRACTURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; OSSIFICATION; OSTEOPOROSIS; POSTOPERATIVE INFECTION; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; WOUND INFECTION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BONE DENSITY; BONE REMODELING; DISEASE SUSCEPTIBILITY; FRACTURE FIXATION; FRACTURE HEALING; FRACTURES, BONE; HIV INFECTIONS; HUMANS; MODELS, BIOLOGICAL; OSTEONECROSIS; RISK FACTORS;

EID: 53649102999     PISSN: 0301620X     EISSN: None     Source Type: Journal    
DOI: 10.1302/0301-620X.90B8.20861     Document Type: Review

References (84)

1. World Health Organisation. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Geneva: World Heath Organisation, 2002.
2. Bayer R, Oppenheimer GM. Pioneers in AIDS care in reflections on the epidemic's early years. N Engl J Med 2006;355:2273-5.
3. Harrison WJ, Lewis CP, Lavy CB. Wound healing after implant surgery in HIV-positive patients. J Bone Joint Surg [Br] 2002;84-B:802-6.
4. Singh K, Moyle GJ. Bone mineral abnormalities in persons with HIV infection: signal or noise? AIDS Read 2006;16:407-10, 413-18.
5. Mondy K, Tebas P. Emerging bone problems in patients infected with human immunodeficiency virus. Clin Infect Dis 2003;36(Suppl 2):101-5.
6. Mondy K, Yarasheski K, Powderly WG, et al. Longitudinal evaluation of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 2003;36:482-90.
7. Soyka LA, Fairfield WP, Klibanski A. Clinical review 117: hormonal determinants and disorders of peak mass in children. J Clin Endocrinol Metab 2000;85:3951-63.
8. UNAIDS. Report on the global AIDS epidemic, 2007 http://data.unaids.org/pub/EP/Slides/2007/2007_epiupdate_en.pdf (date last accessed 25th January 2008).
9. Roberts I, Mohan D, Abbasi K. War on the roads. BMJ 2002;324:1107-8.
10. Hecht R, Alban A, Taylor K, et al. Putting it together: AIDS and the millennium developmental goals. PLoS Med 2006;3:455.
11. Campbell T, Campbell A. Emerging disease burdens and the poor in cities of the developing world. J Urban Health 2007;84(Suppl 3):54-64.
12. Krug E, Mercy JA, Dahlberg LL, Zwi AB. World report on violence and health: Geneva: World Health Organization, 2002. Biomedica 2002;22(Suppl 2):327-36 (in Spanish).
13. Boccellari A, Alvidrez J, Shumway M, et al. Characteristics and psychosocial needs of victims of violent crime identified at a public-sector hospital: data from a large clinical trial. Gen Hosp Psychiatry 2007;29:236-43.
14. Thanh NX, Hang HM, Chuc NT, et al. Does "the injury poverty trap" exist?: a longitudinal study in Bavi, Vietnam. Health Policy 2006;78:249-57.
15. Harrison WJ. HIV/AIDS in trauma and orthopaedic surgery. J Bone Joint Surg [Br] 2005;87-B:1178-81.
16. Ries MD, Barcohana B, Davidson A, Jergensen HE, Paiemont GD. Association between human immunodeficiency virus and osteonecrosis of the femoral head. J Arthroplasty 2002;17:135-9.
17. Harrison WJ, Lavy CBD, Lewis CP. One year follow-up of orthopaedic implants in HIV-positive patients: a prospective study and review of the literature. Int Orthop 2004;28:329-32.
18. Lawal A, Engelson ES, Wang J, Heymsfield SB, Kotler DP. Equivalent osteopenia in HIV-infected individuals studied before and during the era of highly active antiretroviral therapy. AIDS 2001;15:278-80.
19. Knobel H, Guelar A, Valecillo G, Nogués X, Díez A. Osteopenia in HIV-infected patients: is it the disease or is it the treatment? AIDS 2001;15:807-8.
20. Dolan SE, Huang JS, Killilea KM, et al. Reduced bone density in HIV-infected women. AIDS 2004;18:475-83.
21. Bruera D, Luna N, Davud DO, Bergoglio LM, Zamudio J. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 2003;17:1917-23.
22. Arnsten JH, Freeman R, Howard AA, et al. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS 2007;21:617-23.
23. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;359:1761-2.
24. Yin MT, Glesby MJ. Low bone mineral density, HIV infection and women: fracture or fiction? Clin Infect Dis 2006;42:1021-3.
25. Yim M, Dobkin J, Brudney K, et al. Bone mass and mineral metabolism in HIV+ postmenopausal women. Osteoporosis Int 2005;16:1345-52.
26. Pan G, Yang Z, Ballinger SW, McDonald JM. Pathogenesis of osteopenia/osteoporosis induced by highly active anti-retroviral therapy for AIDS. Ann N Y Acad Sci 2006;1068:297-308.
27. Tebas P, Powderly WG, Claxton S, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000;14:63-70.
28. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006;20:2165-74.
29. Amiel C, Ostertag A, Slama L, et al. BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res 2004;19:402-9.
30. Aukrust P, Haug CJ, Ueland T, et al. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalisation of the bone-remodelling process during highly active antiretroviral therapy. J Clin Endocrin of Metab 1999;84:145-50.
31. Ueland T, Bollerslev J, Godang K, et al. Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess: possible role in bone homeostasis. Eur J Endocrinol 2001;145:685-90.
32. Baron R, Rawadi G. Wnt signalling and the regulation of bone mass. Curr Osteoporos Rep 2007;5:73-80.
33. Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodelling. Nat Med 2007;13:156-63.
34. Hernandez Quero J, Centeno O, Munoz-Torres M, et al. Alterations in bone turn-over in HIV-positive patients. Infection 1993;21:220-2.
35. Ramayo E, Gonzázlez-Moreno MP, Macías J, et al. Relationship between osteopenia, free testosterone, and vitamin D metabolite levels in HIV-infected patients with and without highly active antiretroviral therapy. AIDS Res Hum Retrovirus 2005;212:915-21.
36. Teichmann J, Stephan E, Discher T, et al. Changes in calciotropic hormones and biochemical markers of bone metabolism in patients with human immunodeficiency virus infection. Metabolism 2000;49:1134-9.
37. Teichmann J, Stephan E, Lange U, et al. Osteopenia in HIV-infected women prior to highly active antiretroviral therapy. J Infect 2003;46:221-7.
38. Hoang QQ, Sicheri F, Howard AJ, Yang DS. Bone recognition mechanism of porcine osteocalcin from crystal structure. Nature 2003;425:977-80.
39. Stagi S, Bindi G, Galluzi F, et al. Changed bone status in human immunodeficiency virus type 1 (HIV-1) perinatally infected children is related to low serum free IGF-1. Clin Endocrinol (Oxf) 2004;61:692-9.
40. Serrano S, Marinoso ML, Soriano JC, et al. Bone remodelling in human immunodeficiency virus-1-infected patients: a histomorphometric study. Bone 1995;16:185-91.
41. Bolland MJ, Grey AB, Gamble GD, Reid IR. Low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis. J Clin Endocrinol Metab 2007;92:4522-8.
42. Lin D, Rieder MJ. Interventions for the treatment of decreased bone mineral density associated with HIV infection. Cochrane Database Syst Rev 2007;18:CD005645.
43. Negredo E, Martínez E, Cinquegrana D, Estany C, Clotet B. Review article: therapeutic management of bone demineralization in the HIV-infected population. AIDS 2007;21:657-63.
44. Mondy K, Powderly WG, Claxton SA, et al. Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr 2005;38:426-31.
45. Guaraldi G, Orlando G, Madeddu G, et al. Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis. HIV Clin Trials 2004;5:269-77.
46. Einhorn TA, Majeska RJ, Rush EB, et al. The expression of cytokine activity by fracture callus. J Bone Miner Res 1995;10:1272-81.
47. Kon T, Cho T, Aizawa T, et al. Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing. J Bone Miner Res 2001;16:1004-14.
48. Dimitriou R, Tsiridis E, Giannoudis PV. Current concepts of molecular aspects of bone healing. Injury 2005;36:1392-404.
49. Simon AM, Manigrasso MB, O'Connor JP. Cyclo-oxygenase 2 function is essential for bone fracture healing. J Bone Miner Res 2002;17:963-76.
50. Odeh M. The role of tumour necrosis factor-alpha in acquired immunodeficiency syndrome. J Intern Med 1990;228:549-56.
51. Sachdeva N, Yoon HS, Oshima K, et al. Biochip array-based analysis of plasma cytokines in HIV patients with immunological and virological disordance. Scand J Immunol 2007;65:549-54.
52. Aukrust P, Liabakk NB, Muller F, et al. Serum levels of tumor necrosis factor alpha (TNF alpha) and soluble TNG receptors in human immunodeficiency virus type 1 infection: correlations to clinical, immunologic, and virologic parameters. J Infect Dis 1994;169:420-4.
53. Saha RN, Pahan K. Tumor necrosis factor-alpha at the crossroads of neuronal life and death during HIV-associated dementia. J Neurochem 2003;86:1057-71.
54. Buscemi L, Ramonet D, Geiger JD. Human immunodeficiency virus type-1 protein Tat induces tumor necrosis factor-alpha-mediated neurotoxicity. Neurobiol Dis 2007;26:661-70.
55. Monsuez JJ, Escaut L, Teicher E, Charniot JC, Vittecoq D. Cytokines in HIV associated cardiomyopathy. Int J Cardiol 2007;120:150-7.
56. Underwood LE, Wan Wyk JJ. Normal and aberant growth. In: Wilson JD, Foster DW, eds. Williams textbook of endocrinology. Philadelphia: WB Saunders, 1992:1079-138.
57. McCarthy TI, Centrella M, Canalis E. Insulin-like growth factor (IGF) and bone. Connect Tissue Res 1989;20:277-82.
58. Wallace AL, Draper ER, Strachan RK, McCarthy ID, Hughes SP. The effect of devascularisation upon early bone healing in dynamic external fixation. J Bone Joint Surg [Br] 1991;73-B:819-25.
59. Hausman MR, Schaffler MB, Majeska RJ. Prevention of fracture healing in rats by an inhibitor of angiogenesis. Bone 2001;29:560-4.
60. Brown R, Crane L. Avascular necrosis of bone in patients with human immunodeficiency virus infection: report of 6 cases and review of the literature. Clin Infect Dis 2001;32:1221-6.
61. Miller KD, Masur H, Jones EC, et al. High prevalence of osteonecrosis of the femoral head in HIV-infected adults. Ann Intern Med 2002;137:17-25.
62. Monier P, McKown K, Bronze MS. Osteonecrosis complicating highly active antiretroviral therapy in patients infected with human immunodeficiency virus. Clin Infect Dis 2000;31:1488-92.
63. Valencia ME, Barreiro P, Soriano V, et al. Avascular necrosis in HIV-infected patients receiving antiretroviral treatment: study of seven cases. HIV Clin Trials 2003;4:132-6.
64. Molia AC, Strady C, Rouger C, et al. Osteonecrosis in six HIV-infected patients receiving highly active antiretroviral therapy. Ann Pharmacother 2004;38:2050-4.
65. Meyer D, Behrens G, Schmidt RE, Stoll RE. Osteonecrosis of the femoral head in patients receiving HIV protease inhibitors. AIDS 1999;13:1147-8.
66. Grünewald T, Burmester GR, Schüler-Maué W, Hiepe F, Buttgereit F. Antiphospholipid antibodies and CD5+ B cells in HIV infection. Clin Exp Immunol 1999;115:464-71.
67. Erbe M, Rickerts V, Bauersachs RM, Lindhoff-Last E. Acquired protein C and protein S deficiency in HIV-infected patients. Clin Appl Thromb Hemost 2003;9:325-31.
68. Stahl CP, Wideman CS, Spira TJ, et al. Protein S deficiency in men with long-term human immunodeficiency virus infection. Blood 1993;81:1801-7
69. Sorice M, Griggi T, Arcieri P, et al. Protein S and HIV infection: the role of anticardiolipin and anti-protein S antibodies. Thromb Res 1994;73:165-75.
70. Dickson KF, Katzman S, Paiement G. The importance of the blood supply in the healing of tibial fractures. Contemp Orthop 1995;30:489-93.
71. Giannoudis P, Tzioupis C, Almalki T, Buckley R. Fracture healing in osteoporotic fractures: is it really different? A basic science perspective. Injury 2007;38(Suppl 1):90-9.
72. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000;28:3205-10.
73. Wang PS, Solomon DH, Mogun H, Avorn J. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 2000;283:3211-16.
74. Skoglund B, Forslund C, Aspenberg P. Simvastatin improves fracture healing in mice. J Bone Miner Res 2002;17:2004-8.
75. Skoglund B, Aspenberg P. Locally applied Simvastin improves fracture healing in mice. BMC Musculoskeletal Disord 2007;8:98.
76. Huang JS, Rietschel P, Hadigan CM, Rosenthal DI, Grinspoon S. Increased abdominal visceral fat is associated with reduced bone density in HIV-infected men with lipodystrophy. AIDS 2001;15:975-82.
77. Mallon PW, Miller J, Kovacic JC, et al. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men: a randomized, placebo-controlled study. AIDS 2006;20:1003-10.
78. Jellis JE. Orthopaedic surgery and HIV disease in Africa. Int Orthop 1996;20:253-6.
79. Hoekman P, van de Perre P, Nelissen J, et al. Increased frequency of infection after open reduction of fractures in patients who are seropositive for human immunodeficiency virus. J Bone Joint Surg [Am] 1991;73-A:675-9.
80. Giannoudis PV, Schneider E. Principles of fixation of osteoporotic fractures. J Bone Joint Surg [Br] 2006;88-B:1272-8.
81. Norrish AR, Lewis CP, Harrison WJ. Pin-track infection in HIV-positive and HIV-negative patients with open fractures treated by external fixation: a prospective, blinded, case-controlled study. J Bone Joint Surg [Br] 2007;89-B:790-3.
82. Morley J, Marsh S, Drakoulakis E, Pape HC, Giannoudis PV. Does traumatic brain injury result in accelerated fracture healing? Injury 2005;36:363-8.
83. Klein P, Bail HJ, Schell H, et al. Are bone turnover markers capable of predicting consolidation during bone healing? Calcif Tissue Int 2004;75:40-9.
84. Seebeck P, Bail HJ, Exner C, et al. Do serological tissue turnover markers represent callus formation during fracture healing? Bone 2005;37:669-77.